These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 10076732)

  • 1. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
    Specht L; Larsen SK; Hansen HS
    Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
    Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Gedlicka C; Formanek M; Selzer E; Burian M; Kornfehl J; Fiebiger W; Cartellieri M; Marks B; Kornek GV
    Oncology; 2002; 63(2):145-50. PubMed ID: 12239449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
    Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
    Janinis J; Papadakou M; Xidakis E; Boukis H; Poulis A; Panagos G; Lefantzis D
    Am J Clin Oncol; 2000 Apr; 23(2):128-31. PubMed ID: 10776971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
    J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
    Glisson BS; Murphy BA; Frenette G; Khuri FR; Forastiere AA
    J Clin Oncol; 2002 Mar; 20(6):1593-9. PubMed ID: 11896109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
    Baur M; Kienzer HR; Schweiger J; DeSantis M; Gerber E; Pont J; Hudec M; Schratter-Sehn AU; Wicke W; Dittrich C
    Cancer; 2002 Jun; 94(11):2953-8. PubMed ID: 12115384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
    Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
    Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
    Basaran M; Bavbek SE; Güllü I; Demirelli F; Sakar B; Tenekeci N; Altun M; Yalçin S; Onat H
    J Chemother; 2002 Apr; 14(2):207-13. PubMed ID: 12017379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
    Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
    J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel.
    Schöffski P; Weihkopf T; Ganser A
    Anticancer Res; 1998; 18(6B):4751-6. PubMed ID: 9891552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.